Innovative Nanotechnological Formulations to Reach the Hepatic Stellate Cell

Klaas Poelstra*

*Corresponding author for this work

Research output: Contribution to journalArticleProfessional

48 Downloads (Pure)


Purpose of Review: Treatment of liver fibrosis benefits from hepatic stellate cell (HSC)-specific delivery. Since the description of first carrier to HSC, many developments have taken place in this area. The purpose is to give an overview of the different carriers and homing moieties that are available for HSC targeting and illustrate the opportunities and hurdles they provide.
Recent Findings: There is a growing number of homing devices to deliver drugs to HSC, and options to deliver siRNA to HSC have emerged. Other developments include controlling corona formation, development of linker technology, and design of theranostic approaches. We are on the eve of reaching the clinic with innovative HSC-specific compounds.
Summary: An overview of different core molecules is presented together with an overview of targeting strategies toward different receptors on HSC, providing a versatile toolbox. Many therapeutics, ranging from small chemical entities and proteins to RNA- or DNA-modulating substances, have already been incorporated in these constructs in the recent years.
Original languageEnglish
Pages (from-to)13-22
Number of pages10
JournalCurrent Tissue Microenvironment Reports
Publication statusPublished - 31-Mar-2020


  • Liver fibrosis
  • Hepatic stellate cell
  • Drug targeting
  • Nanomedicine
  • Nanotechnology
  • Antifibrotic drugs

Cite this